S ynthetic cannabinoids (K2 or spice) have been abused for decades as an alternative to marijuana that is both cheaper and harder to detect. In 2018, tainting of synthetic cannabinoids with brodifacoum (often used as a rodenticide), a vitamin-K antagonist with 100-fold higher potency than warfarin, has resulted in an epidemic of coagulopathy in users of these substances across the United States. 1, 2 Patients typically present with a markedly elevated prothrombin time/international normalized ratio and in most cases also experience unexplained bleeding. The antidote, phytonadione (vitamin K 1 ), is almost a century old and relatively simple to manufacture compared with modern-day biologics. However, the pricing of this generic, single-source pharmaceutical has made the cost of therapy for brodifacoum toxicity prohibitively expensive.
Initial management of brodifacoum exposure involves initiation of oral vitamin K 1 at doses as high as 50 mg every 6 hours, subsequently titrated to serial prothrombin time/international normalize ratios and achievement of hemostasis. 3 Treatment with phytonadione may be required for weeks or months to mitigate the effects of brodifacoum due to its prolonged half-life (16-34 days). In the United States, phytonadione is available only in 5-mg tablets, which are associated with significant cost (US $70.51 per tablet). This is in stark contrast to the cost of veterinary-grade vitamin K 1 50-mg tablets (US $0.61 per tablet), priced at more than 1000-fold lower cost per milligram than the US Food and Drug Administrationeapproved product for use in humans. 4 Although the use of unregulated veterinary-grade pharmaceutical products in humans cannot be condoned, this pricing discrepancy highlights the severity of chronic price gouging among single-source US Food and Drug Administrationeapproved medications. The single-source intravenous formulation of phytonadione is significantly less costly (US $60.30 per 10-mg ampule) than the tablet formulation. Many institutions preferentially administer the intravenous phytonadione formulation enterally as a cost-saving strategy. Implementation of this practice is associated with an estimated cost avoidance of approximately US $3700 per admission based on utilization patterns at our institution. However, widespread adoption of this practice during the ongoing brodifacoum epidemic has resulted in interruption of intravenous phytonadione supply, potentially increasing the cost of care for these cases moving forward if this disruption persists. The lack of health insurance coverage in the demographic of synthetic cannabinoid users further complicates management, because many patients require high-dose oral phytonadione administration for several months after discharge. In multiple cases listed below, our institution has vouchered several thousand US dollars' worth of phytonadione to ensure safe discharge for patients who lack prescription drug coverage.
Initial treatment of patients presenting with life-threatening bleeding also includes administration of up to 5000 units (US $13,850) of 4-factor prothrombin complex concentrate (Kcentra, CSL Behring) to rapidly achieve hemostasis, further increasing health care cost. Moreover, an ongoing nationwide shortage of Kcentra may necessitate consideration of alternative treatment approaches for patients with severe bleeding in the near future.
Nine cases of brodifacoum toxicity have been treated at our institution since April 1, 2018, and we expect this trend to continue in the months ahead. The total cost of inpatient antidote administration for the 7 patients discharged from our health system since April 2018 are described in the Table. Because of the increasing frequency of these presentations and cost of care, we have established a guidance document for providers to triage empiric treatment on the basis of laboratory and clinical presentation, but even with this protocol the cost of brodifacoum toxicity management remains unacceptably high.
Urgent measures are required to improve access to phytonadione. The Bausch Foundation, an independent charitable foundation of the makers of phytonadione tablets, donated 800,000 tablets to the Illinois Department of Public Health, but outpatient access to adequate supply of phytonadione remains problematic in other parts of the country. 5 The recent 55-fold increase in price of the 60-year-old antibiotic pyrimethamine has been well publicized, but price gouging has affected our society for decades, both within and outside of the American health care system. 6 For example, in 1984, the New York Times exposed the Defense Department procurement scandal when it reported that hammers cost the Defense Department more than US $400 each. 7 With US $700 price tags for 60-year-old antibiotics and century-old vitamins, and ongoing shortages of intravenous fluids, the American health care system appears to have reached its "$400 hammer moment." CONCLUSION Although multiple factors are responsible for the unacceptably high cost of care for rodenticide-induced coagulopathy treatment, this is a clear example of market failure in a noncompetitive monopoly. Innovative solutions have been proposed, such as generic drug manufacturing by not-for-profit hospital health-systems and importation of "sole source" generics, but could take several years to come to fruition.
8 Similar problems will continue to arise unless new regulations can control such outrageous drug pricing strategies that restrict patient access to life-saving medicines. The cost, complexity, and challenge of treating a vitamin deficiency state is a testament to some of the problems burdening health care delivery in the United States. Unless systemic changes in policies for drug manufacturing and distribution in the United States are instituted, price gouging will continue to be our new normal. 
